FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1567665160> ?p ?o ?g. }

• W1567665160 endingPage "682" @default.
• W1567665160 startingPage "677" @default.
• W1567665160 abstract "Objectives To evaluate the efficacy and safety of tamsulosin dose increase to 0.4 mg daily in A sian patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia refractory to tamsulosin 0.2 mg treatment. Methods We carried out a 12‐week, single‐center, randomized, placebo‐controlled trial in 220 patients. Patients treated with 0.2 mg tamsulosin daily without other lower urinary tract symptoms secondary to benign prostatic hyperplasia medication for more than 3 months and refractory to this treatment were enrolled. We defined “refractory” as an International Prostate Symptom Score of 13 or greater and a maximum flow rate of 15 or under despite medication. Patients with a surgical history related to lower urinary tract symptoms secondary to benign prostatic hyperplasia or a postvoid residual of 150 mL or greater were excluded. Eligible patients were randomly assigned to the 0.4 mg group (two tablets of 0.2 mg tamsulosin once daily) or the 0.2 mg group (one tablet of 0.2 mg tamsulosin and one tablet of placebo once daily). International Prostate Symptom Score, maximum flow rate, blood pressure, heart rate, and adverse events were compared between the two groups at 4 weeks and 12 weeks. Results A total of 220 patients were enrolled and analyzed. There were no differences in baseline characteristics between the two groups. After 12 weeks of medication, the International Prostate Symptom Score was not different between the two groups. However, the improvement in maximum flow rate was greater in the 0.4 mg group than the 0.2 mg group (3.0 ± 0.48 mL/s vs −0.25 ± 0.30 mL/s, P < 0.01). The proportion of patients who showed an increase in maximum flow rate of more than 5 mL/s was 10.9% in the 0.2 mg group versus 16.3% in the 0.4 mg group ( P = 0.209). There were no significant differences in bother score or postvoid residual between the two groups. Systolic and diastolic blood pressure, and heart rate were also not different between the two groups. The incidence of adverse events was 10.9% in the 0.2 mg group (dizziness 5.5%; abnormal ejaculation 1.8%; palpitation 1.8%; and headache 1.8%) and 9.09% in the 0.4 mg group (dizziness 3.6%; abnormal ejaculation 1.8%; palpitations 1.8%; and headache 1.8%). Conclusions Tamsulosin 0.4 mg appears to be a safe treatment regimen for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia in A sian patients who do not respond to 0.2 mg treatment. Increasing the dose of tamsulosin results in a significant improvement in maximum flow rate without any increase in cardiovascular complications." @default.
• W1567665160 created "2016-06-24" @default.
• W1567665160 creator A5030248447 @default.
• W1567665160 creator A5035206328 @default.
• W1567665160 creator A5055805396 @default.
• W1567665160 creator A5056339615 @default.
• W1567665160 creator A5068341840 @default.
• W1567665160 date "2014-04-13" @default.
• W1567665160 modified "2023-10-03" @default.
• W1567665160 title "Efficacy and tolerability of tamsulosin 0.4 mg in Asian patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia refractory to tamsulosin 0.2 mg: A randomized placebo controlled trial" @default.
• W1567665160 cites W1691351443 @default.
• W1567665160 cites W1967694704 @default.
• W1567665160 cites W1979336330 @default.
• W1567665160 cites W1983094092 @default.
• W1567665160 cites W1983391475 @default.
• W1567665160 cites W1996195167 @default.
• W1567665160 cites W2017988838 @default.
• W1567665160 cites W2064690405 @default.
• W1567665160 cites W2116691655 @default.
• W1567665160 cites W2135421268 @default.
• W1567665160 cites W2341507669 @default.
• W1567665160 cites W4319720823 @default.
• W1567665160 doi "https://doi.org/10.1111/iju.12412" @default.
• W1567665160 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24725169" @default.
• W1567665160 hasPublicationYear "2014" @default.
• W1567665160 type Work @default.
• W1567665160 sameAs 1567665160 @default.
• W1567665160 citedByCount "12" @default.
• W1567665160 countsByYear W15676651602014 @default.
• W1567665160 countsByYear W15676651602015 @default.
• W1567665160 countsByYear W15676651602017 @default.
• W1567665160 countsByYear W15676651602018 @default.
• W1567665160 countsByYear W15676651602019 @default.
• W1567665160 countsByYear W15676651602020 @default.
• W1567665160 countsByYear W15676651602021 @default.
• W1567665160 countsByYear W15676651602022 @default.
• W1567665160 countsByYear W15676651602023 @default.
• W1567665160 crossrefType "journal-article" @default.
• W1567665160 hasAuthorship W1567665160A5030248447 @default.
• W1567665160 hasAuthorship W1567665160A5035206328 @default.
• W1567665160 hasAuthorship W1567665160A5055805396 @default.
• W1567665160 hasAuthorship W1567665160A5056339615 @default.
• W1567665160 hasAuthorship W1567665160A5068341840 @default.
• W1567665160 hasConcept C121332964 @default.
• W1567665160 hasConcept C121608353 @default.
• W1567665160 hasConcept C126322002 @default.
• W1567665160 hasConcept C126894567 @default.
• W1567665160 hasConcept C142424586 @default.
• W1567665160 hasConcept C142724271 @default.
• W1567665160 hasConcept C168563851 @default.
• W1567665160 hasConcept C197934379 @default.
• W1567665160 hasConcept C204787440 @default.
• W1567665160 hasConcept C27081682 @default.
• W1567665160 hasConcept C2776235491 @default.
• W1567665160 hasConcept C2776547966 @default.
• W1567665160 hasConcept C2777562237 @default.
• W1567665160 hasConcept C2778375690 @default.
• W1567665160 hasConcept C2779478474 @default.
• W1567665160 hasConcept C2780542891 @default.
• W1567665160 hasConcept C71924100 @default.
• W1567665160 hasConcept C87355193 @default.
• W1567665160 hasConceptScore W1567665160C121332964 @default.
• W1567665160 hasConceptScore W1567665160C121608353 @default.
• W1567665160 hasConceptScore W1567665160C126322002 @default.
• W1567665160 hasConceptScore W1567665160C126894567 @default.
• W1567665160 hasConceptScore W1567665160C142424586 @default.
• W1567665160 hasConceptScore W1567665160C142724271 @default.
• W1567665160 hasConceptScore W1567665160C168563851 @default.
• W1567665160 hasConceptScore W1567665160C197934379 @default.
• W1567665160 hasConceptScore W1567665160C204787440 @default.
• W1567665160 hasConceptScore W1567665160C27081682 @default.
• W1567665160 hasConceptScore W1567665160C2776235491 @default.
• W1567665160 hasConceptScore W1567665160C2776547966 @default.
• W1567665160 hasConceptScore W1567665160C2777562237 @default.
• W1567665160 hasConceptScore W1567665160C2778375690 @default.
• W1567665160 hasConceptScore W1567665160C2779478474 @default.
• W1567665160 hasConceptScore W1567665160C2780542891 @default.
• W1567665160 hasConceptScore W1567665160C71924100 @default.
• W1567665160 hasConceptScore W1567665160C87355193 @default.
• W1567665160 hasIssue "7" @default.
• W1567665160 hasLocation W15676651601 @default.
• W1567665160 hasLocation W15676651602 @default.
• W1567665160 hasOpenAccess W1567665160 @default.
• W1567665160 hasPrimaryLocation W15676651601 @default.
• W1567665160 hasRelatedWork W1962507201 @default.
• W1567665160 hasRelatedWork W1978630268 @default.
• W1567665160 hasRelatedWork W2013459993 @default.
• W1567665160 hasRelatedWork W2033685093 @default.
• W1567665160 hasRelatedWork W2110308314 @default.
• W1567665160 hasRelatedWork W2118368078 @default.
• W1567665160 hasRelatedWork W2134005946 @default.
• W1567665160 hasRelatedWork W2180012585 @default.
• W1567665160 hasRelatedWork W2786468047 @default.
• W1567665160 hasRelatedWork W4285297998 @default.
• W1567665160 hasVolume "21" @default.
• W1567665160 isParatext "false" @default.
• W1567665160 isRetracted "false" @default.
• W1567665160 magId "1567665160" @default.

• next